Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA.

Zhang Q, Hu G, Yang Q, Dong R, Xie X, Ma D, Shen K, Kong B.

Gynecol Oncol. 2013 Jul;130(1):132-9. doi: 10.1016/j.ygyno.2013.04.048. Epub 2013 Apr 25.

PMID:
23623832
2.

Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer.

Wang B, Yu L, Yang GZ, Luo X, Huang L.

Asian Pac J Cancer Prev. 2015;16(7):3003-7.

3.

Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.

Bondurant AE, Huang Z, Whitaker RS, Simel LR, Berchuck A, Murphy SK.

Gynecol Oncol. 2011 Dec;123(3):581-7. doi: 10.1016/j.ygyno.2011.08.029. Epub 2011 Sep 28.

PMID:
21955482
4.

Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARĪ²2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.

Yamamoto N, Nakayama T, Kajita M, Miyake T, Iwamoto T, Kim SJ, Sakai A, Ishihara H, Tamaki Y, Noguchi S.

Breast Cancer Res Treat. 2012 Feb;132(1):165-73. doi: 10.1007/s10549-011-1575-2. Epub 2011 May 19.

PMID:
21594664
5.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

6.
7.

Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.

Abou-Zeid AA, Azzam AZ, Kamel NA.

Scand J Clin Lab Invest. 2011 Nov;71(7):542-7. doi: 10.3109/00365513.2011.590224. Epub 2011 Jul 6.

PMID:
21728901
8.

Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients.

Fujita N, Nakayama T, Yamamoto N, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Morimoto K, Tamaki Y, Noguchi S.

Oncology. 2012;83(5):273-82. doi: 10.1159/000342083. Epub 2012 Sep 5.

PMID:
22964822
9.

A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients.

Nakayama G, Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S, Nakao A.

Anticancer Res. 2007 May-Jun;27(3B):1459-63.

10.

Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.

Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL, Cairns P.

Cancer Res. 2004 Sep 15;64(18):6476-81.

11.

Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.

Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM.

Gynecol Oncol. 2012 Mar;124(3):582-8. doi: 10.1016/j.ygyno.2011.11.026. Epub 2011 Nov 22.

PMID:
22115852
12.

Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer.

He Q, Chen HY, Bai EQ, Luo YX, Fu RJ, He YS, Jiang J, Wang HQ.

Cancer Genet Cytogenet. 2010 Oct 1;202(1):1-10. doi: 10.1016/j.cancergencyto.2010.05.018.

PMID:
20804913
13.

Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer.

Wang B, Yu L, Luo X, Huang L, Li QS, Shao XS, Liu Y, Fan Y, Yang GZ.

Oncol Lett. 2017 Jul;14(1):217-223. doi: 10.3892/ol.2017.6111. Epub 2017 May 3.

14.

[Detection of free tumor-related DNA in the serum of breast cancer patients].

Zhang JJ, Ouyang T, Wan WH, Deng GR.

Zhonghua Zhong Liu Za Zhi. 2007 Aug;29(8):609-13. Chinese.

PMID:
18210882
15.

Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer.

Dong R, Yu J, Pu H, Zhang Z, Xu X.

J Int Med Res. 2012;40(2):681-6.

PMID:
22613430
16.

Validation of serum biomarkers for detection of early-stage ovarian cancer.

Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, Reddy S, Farias-Eisner R.

Am J Obstet Gynecol. 2009 Jun;200(6):639.e1-5. doi: 10.1016/j.ajog.2008.12.042. Epub 2009 Mar 14.

PMID:
19285648
18.

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer.

Tcherkassova J, Abramovich C, Moro R, Chen C, Schmit R, Gerber A, Moro R.

Tumour Biol. 2011 Aug;32(4):831-8. doi: 10.1007/s13277-011-0186-1. Epub 2011 May 28.

19.

Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.

Arakawa N, Kobayashi H, Yonemoto N, Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y, Hirahara F, Hirano H, Miyagi E.

PLoS One. 2016 Oct 31;11(10):e0165609. doi: 10.1371/journal.pone.0165609. eCollection 2016.

20.

[Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].

Yang ZJ, Yang G, Jiang YM, Ran YL, Yang ZH, Zhang W, Zhang JQ, Pan ZM, Li L.

Zhonghua Fu Chan Ke Za Zhi. 2011 Feb;46(2):113-8. Chinese.

PMID:
21426769

Supplemental Content

Support Center